Tellgen Corp (300642) - Total Liabilities

Latest as of March 2026: CN¥539.79 Million CNY ≈ $78.99 Million USD

Based on the latest financial reports, Tellgen Corp (300642) has total liabilities worth CN¥539.79 Million CNY (≈ $78.99 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Tellgen Corp - Total Liabilities Trend (2012–2025)

This chart illustrates how Tellgen Corp's total liabilities have evolved over time, based on quarterly financial data. See 300642 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Tellgen Corp Competitors by Total Liabilities

The table below lists competitors of Tellgen Corp ranked by their total liabilities.

Company Country Total Liabilities
Text S.A.
WAR:TXT
Poland zł96.26 Million
Bleichroeder Acquisition Corp. II Class A Ordinary Shares
NASDAQ:BBCQ
USA $16.75 Million
DYNAGREEN EN.PR.GR.H YC 1
F:DYN
Germany €13.25 Billion
Cotec Construction JSC
VN:CTD
Vietnam ₫25.18 Trillion
Hutchison Telecommunications (Australia) Ltd
AU:HTA
Australia AU$51.03 Million
Giantplus Technology Co Ltd
TW:8105
Taiwan NT$3.00 Billion
Zhubo Design
SHE:300564
China CN¥326.39 Million
Bintang Oto Global Tbk PT
JK:BOGA
Indonesia Rp343.96 Billion

Liability Composition Analysis (2012–2025)

This chart breaks down Tellgen Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tellgen Corp (300642) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 5.38 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.38 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.27 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tellgen Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tellgen Corp (2012–2025)

The table below shows the annual total liabilities of Tellgen Corp from 2012 to 2025.

Year Total Liabilities Change
2025-12-31 CN¥576.38 Million
≈ $84.34 Million
+149.57%
2024-12-31 CN¥230.94 Million
≈ $33.79 Million
+60.33%
2023-12-31 CN¥144.05 Million
≈ $21.08 Million
-21.74%
2022-12-31 CN¥184.07 Million
≈ $26.94 Million
+79.43%
2021-12-31 CN¥102.59 Million
≈ $15.01 Million
-2.48%
2020-12-31 CN¥105.19 Million
≈ $15.39 Million
+35.13%
2019-12-31 CN¥77.84 Million
≈ $11.39 Million
-1.07%
2018-12-31 CN¥78.68 Million
≈ $11.51 Million
+100.17%
2017-12-31 CN¥39.31 Million
≈ $5.75 Million
-24.23%
2016-12-31 CN¥51.88 Million
≈ $7.59 Million
+34.84%
2015-12-31 CN¥38.47 Million
≈ $5.63 Million
+25.22%
2014-12-31 CN¥30.72 Million
≈ $4.50 Million
-6.56%
2013-12-31 CN¥32.88 Million
≈ $4.81 Million
+270.61%
2012-12-31 CN¥8.87 Million
≈ $1.30 Million
--

About Tellgen Corp

SHE:300642 China Medical Devices
Market Cap
$297.79 Million
CN¥2.04 Billion CNY
Market Cap Rank
#14974 Global
#4439 in China
Share Price
CN¥12.52
Change (1 day)
-3.10%
52-Week Range
CN¥12.52 - CN¥31.30
All Time High
CN¥46.24
About

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more